Table 3.
Association between the iceA2 status and clinical outcomes
| Group/subgroup | OR (95% CI) | P-value | I2 (%) | Phet | Analysis model |
|---|---|---|---|---|---|
| Total | |||||
| PUD vs gastritis/NUD | 1.07 (0.85, 1.33) | 0.58 | 27 | 0.15 | FE |
| GC vs gastritis/NUD | 1.27 (0.89, 1.82) | 0.19 | 0 | 0.65 | FE |
| GC vs PUD | 0.97 (0.69, 1.36) | 0.86 | 0 | 0.74 | FE |
| People’s Republic of China | |||||
| PUD vs gastritis/NUD | 1.19 (0.90, 1.58) | 0.21 | 43 | 0.07 | RE |
| GC vs gastritis/NUD | 1.24 (0.70, 2.18) | 0.46 | 0 | 0.65 | FE |
| GC vs PUD | 0.92 (0.55, 1.53) | 0.74 | 0 | 0.89 | FE |
| Other countries | |||||
| PUD vs gastritis/NUD | 0.87 (0.60, 1.26) | 0.48 | 0 | 0.62 | FE |
| GC vs gastritis/NUD | 1.29 (0.81, 2.05) | 0.28 | 0 | 0.65 | FE |
| GC vs PUD | 1.01 (0.65, 1.59) | 0.95 | 10 | 0.35 | FE |
Abbreviations: PUD, peptic ulcer disease; NUD, nonulcer dyspepsia; GC, gastric carcinoma; OR, odds ratio; I2, I-squared; Phet, P-value for heterogeneity test; FE, fixed-effect model; RE, random-effect model; CI, confidence interval.